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RESEARCH ARTICLE Open Access
Immunization with one Theileria parva
strain results in similar level of CTL strain-
specificity and protection compared to
immunization with the three-component
Muguga cocktail in MHC-matched animals
Lucilla Steinaa1* , Nicholas Svitek1, Elias Awino1, Thomas Njoroge1, Rosemary Saya1, Ivan Morrison2 and Philip Toye1
Abstract
Background: The tick-borne protozoan parasite Theileria parva causes a usually fatal cattle disease known as East
Coast fever in sub-Saharan Africa, with devastating consequences for poor small-holder farmers. Immunity to T. parva,
believed to be mediated by a cytotoxic T lymphocyte (CTL) response, is induced following natural infection and after
vaccination with a live vaccine, known as the Infection and Treatment Method (ITM). The most commonly used version
of ITM is a combination of parasites derived from three isolates (Muguga, Kiambu 5 and Serengeti-transformed), known
as the “Muguga cocktail”. The use of a vaccine comprising several strains is believed to be required to induce a broad
immune response effective against field challenge. In this study we investigated whether immunization with the
Muguga cocktail induces a broader CTL response than immunization with a single strain (Muguga).
Results: Four MHC haplotype-matched pairs of cattle were immunized with either the trivalent Muguga cocktail
or the single Muguga strain. CTL specificity was assessed on a panel of five different strains, and clonal responses
to these strains were also assessed in one of the MHC-matched pairs. We did not find evidence for a broader CTL
response in animals immunized with the Muguga cocktail compared to those immunized with the Muguga strain
alone, in either the bulk or clonal CTL analyses. This was supported by an in vivo trial in which all vaccinated
animals survived challenge with a lethal dose of the Muguga cocktail vaccine stabilate.
Conclusion: We did not observe any substantial differences in the immunity generated from animals immunized
with either Muguga alone or the Muguga cocktail in the animals tested here, corroborating earlier results showing limited
antigenic diversity in the Muguga cocktail. These results may warrant further field studies using single T. parva strains as
future vaccine candidates.
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Background
Theileria parva is a tick-borne protozoan parasite which
causes an acute and usually fatal cattle disease, known as
East Coast fever, in eastern, central and southern Africa.
The parasite infects bovine lymphocytes, which subse-
quently undergo blast transformation and rapid multipli-
cation [1]. In susceptible animals, this usually results in
overwhelming parasitosis and death within 2 to 4 weeks
of infection.
Cattle which recover from natural infection can de-
velop a strong immunity to subsequent challenge. This
has been exploited to develop a vaccination procedure
known as the “Infection and Treatment Method” (ITM)
in which live sporozoites are administered simultan-
eously with oxytetracycline. The main protective mech-
anism in both vaccinated and naturally recovered
animals is believed to be CD8+ cytotoxic T lymphocyte
(CTL) killing of infected lymphocytes. Thus, adoptive
transfer of CD8+ cells from immunized animals has been
demonstrated to protect naïve animals from challenge
[2]. Furthermore, it has been shown that the time point
of recovery correlates with a peak of CD8+ cells in the
blood of the infected animals [3].
Early experiments in the development of the ITM vac-
cine revealed the presence of strain specificity through
infection and challenge trials where animals were immu-
nized with one strain and challenged with a heterologous
strain. While good protection was often obtained follow-
ing the inoculation of single strains, it did not always
extend to heterologous challenge [4]. It was subse-
quently shown that a combination of three strains
(Muguga, Serengeti-transformed and Kiambu 5)
provided better protection than single strains. The mix-
ture, known as the “Muguga cocktail”, is the basis of a
commercial ITM vaccine which appears to provide
broad protection against T. parva in the field, so far best
explored in Tanzania [5, 6]. It should be noted that in
experiments involving single isolates, some cross-
protection was observed with a notable exception being
if animals vaccinated with the Muguga strain or Kilifi
strain were challenged with Marikebuni [4, 7, 8], sug-
gesting that Marikebuni is antigenically quite distinct.
Strain specificity has also been observed in in vitro CTL
assays and reflects the in vivo immune status [3, 9–11]. A
possible explanation for the strain specificity of the CTL
response to T. parva is based on two phenomena –
immunodominance and antigenic diversity. Immunodo-
minance, where the immune response is directed to a very
limited number of antigens in individual animals, is com-
monly observed in viral infections [12–15] and also in
other infectious diseases and cancers [16–18]. In T. parva
infections, indications of immunodominance came with
initial analyses of the immune response where, in some
cases, it was possible to show that CTL restriction was
mediated by a single class I MHC molecule [19, 20] des-
pite the presence of many potential epitopes expressed by
the parasite genome, which is predicted to encode 4034
genes [21, 22], and a T cell receptor (TCR) repertoire cap-
able of reacting to a wide variety of epitopes. More re-
cently, with the discovery of CTL antigens [23], a study
was performed to shed light on the issue of immunodomi-
nance [24]. Findings from this work suggest that one or a
few MHC alleles in individual animals govern the specifi-
city of the immune response elicited by infection or vac-
cination and are crucial for the outcome of a later
challenge with genotypically different parasites.
The most plausible explanation for the broad protec-
tion offered by the Muguga cocktail, is that the mixture
of the parasites in the cocktail, provides a more diverse
set of antigens which potentially can induce a CTL re-
sponse of broader antigenic specificity than inoculation
with any of the individual components or single strains,
and thus provide better protection against heterologous
parasites encountered in the field. To test this hypoth-
esis, we compared the specificities for different parasite
strains of CTL induced in animals immunized by ITM
with the Muguga cocktail with those generated by the
Muguga stabilate alone. To minimize any effect of the
MHC background in individual animals, which is known
to influence the selection of antigens recognized by the
CTLs, the responses were compared in MHC haploiden-
tical pairs of cattle. Analysis of the CTL response at the
clonal level was also undertaken for one haplotype
matched pair. All haploidentical pairs of cattle were
challenged with the Muguga cocktail to uncover any
antigenic differences in the in vivo CTL response.
Methods
Animals and MHC class I typing
All animal experiments were reviewed and approved by
the Institutional Animal Care and Use Committee at
International Livestock Research Institute (ILRI). Eight
Bos taurus cattle (five Friesian and three Ayrshire) were
bought from farms in the Nyeri area in Kenya. They
were screened free for tickborne diseases including T.
parva, and BoLA typed using a combination of serology
(ELISA using antibodies defining particular MHC haplo-
types), IFNγ ELISPOT assay using PBMC from the cattle
pulsed with Tp1214–224 and a peptide-specific CTL line,
and by PCR using haplotype specific primers followed
by sequencing, essentially as described before [25]. Four
haploidentical pairs of the following MHC haplotypes
were selected for the study: A10/A12, A12/A14, A15/
A18, A11/A15 (Table 1). Animals were kept in standard
pens and were fed normally. At the end of the experi-
ment, animals were returned to the farm and eventually
slaughtered for meat. Two control animals, which devel-
oped disease, were euthanized for humane reasons using
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an overdose of Euthatal (Pentobarbital sodium, 200 mg/
ml), 1 ml Euthatal per 1.4 kg body weight, given intra-
venously, after restraining the animals.
Immunization
Each of the haplotype-matched pairs of cattle was inocu-
lated subcutaneously in front and below the right ear
with either the Muguga stabilate 3308 or the Muguga
cocktail vaccine stabilate ILRI0801 [26] and treated im-
mediately with long acting oxytetracyclin.
Parasitized cell lines
Cell lines infected with T. parva were established by in-
fection of autologous PBMC in vitro with sporozoites as
described previously [27]. The sporozoites were from the
cloned stabilates Marikebuni 3292, Muguga 3308, Boleni
3230, Uganda 3645, derived from 3569 [28], and
Mariakani 3212 (unpublished). In addition, cell lines
were established using sporozoites of the ILRI0801 refer-
ence stabilates: Muguga (4230), Serengeti (4229),
Kiambu 5 (4228). These are stabilates of the individual
Muguga cocktail components made from the same pro-
duction ticks as the ILRI0801 vaccine [26].
Generation of CTL
CTL bulk cultures were generated and maintained in
RPMI 1640 (Sigma-Aldrich, St.Louis, MO, USA) supple-
mented with 10% FBS (Thermo Fisher Scientific,
Waltham, MA, USA), 2 mM L-glutamin (Sigma-Aldrich,
St.Louis, MO, USA), 50 μM 2-mercaptoethanol (Sigma-
Aldrich, St.Louis, MO, USA), 100 IU of penicillin/ml
(Sigma-Aldrich, St.Louis, MO, USA), 100 μg of strepto-
mycin/ml (Sigma-Aldrich, St.Louis, MO, USA), 50 μg of
gentamicin/ml, (Sigma-Aldrich, St.Louis, MO, USA) 10%
TCGF (Conditioned media from ConA blasts).
CTL were generated essentially as described [27, 29].
Briefly, PBMC were re-stimulated three times with irradi-
ated autologous T. parva-infected cell lines. CTL from an-
imals immunized with the vaccine were generated by
stimulating with equal fractions of three cell lines infected
with one of the three vaccine reference stabilates. CTL
from the Muguga- immunized animals were stimulated
with the Muguga-infected cell line only. The remainder of
the procedure was as described previously [27, 29].
Generation of CD8+ CTL clones
Clones were generated by purifying CD8+ cells after two
restimulations as described above. Enrichment of CD8+
cells was achieved by incubating the CTL line for
30 min with mouse-anti-bovine CD8 mAb ILA105
(ILRI) diluted 1:500 in PBS + 2% FBS. Cells were washed
twice in PBS + 2%FBS, labeled with magnetic beads at-
tached to goat-anti-mIgG (Miltenyi Biotec, Bergish
Gladbach, Germany) and purified according to the
protocol provided by the manufacturer. Purified CD8+
cells were then seeded by limiting dilutions in 96-well
plates using 2 × 104 irradiated PBMC as filler cells as
previously described [27].
CTL lines and clones were generated and maintained in
RPMI 1640 medium (Sigma-Aldrich, St. Louis, MO, USA)
supplemented with 10% FBS (Thermo Fisher Scientific,
Waltham, MA, USA), 2 mM L-glutamine, 50 μM 2-
mercaptoethanol, 100 IU/ml of penicillin, 100 μg/ml of
streptomycin, 50 μg/ml of gentamicin, (all from Sigma-
Aldrich, St. Louis, MO, USA) and 10% inactivated ConA
supernatant (conditioned media from ConA blasts).
Cytotoxicity assay
A standard 4 h release assay using 51Cr-labeled target cells
was used to measure cytotoxicity. 51Cr was obtained from
American Radiolabeled Chemicals, Inc., St. Louis, MO,
USA. Supernatants were counted using Lumaplates
(PerkinElmer, Waltham, MA, USA) in a TopCounter
(PerkinElmer, Waltham, MA, USA). The cytotoxicity was
calculated as: (experimental release-spontaneous release/
total release-spontaneous release). Target cells were either
T. parva-infected autologous PBMC using MHC-
mismatched T. parva-infected cell lines as controls. In
one case (BH055), autologous uninfected PBMC were
used as control. Each CTL was tested in dilutions using a
fixed number of target cells. Each dilution was tested in
triplicate. Cytotoxicity at an effector:target ratio of 10:1
was used to compare between CTL derived from different
animals and between different target cells.
Challenge experiment
Cattle were challenged with the Muguga cocktail vaccine
stabilate ILRI0801, without oxytetracycline. The vaccine
(2 ml neat) was injected subcutaneously in front of and
Table 1 Cattle used in the study
Calf Breed MHC Class 1
Haplotype
Alleles Immunization
BG033 Friesian A10/A12 N*00201, N*01901 Muguga (3308)
BG042 Friesian A10/A12 N*00201, N*01901 Muguga cocktail
(0801)
BG053 Ayrshire A12/A14 N*01901, N*02301 Muguga (3308)
BG051 Ayrshire A12/A14 N*01901, N*02301 Muguga cocktail
(0801)
BG052 Friesian A15/A18 N*00901, N*01302 Muguga (3308)
BG056 Friesian A15/A18 N*00901, N*01302 Muguga cocktail
(0801)
BH055 Ayrshire A11/A15 N*01802, N*00902 Muguga (3308)
BH047 Friesian A11/A15 N*01802, N*00902 Muguga cocktail
(0801)
The breed, MHC Class I haplotype and associated MHC alleles of the cattle
included in the study are shown. Within each of the haplotype matched pairs
of cattle, one was immunized with the single T. parva strain Muguga 3308 and
the other was immunized with the Muguga cocktail 0801 using ITM
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below the right ear. Animals were monitored for the re-
quired clinical parameters to determine the severity of
disease according to the Rowlands index [30].
Results
Similar strain specificities of CTL from haplotype-matched
animals immunized by ITM with either T. parva Muguga
or the Muguga cocktail
Eight cattle comprising four haploidentical pairs were
immunized by ITM with either the Muguga strain
(3308) or the trivalent Muguga cocktail (ILRI0801), as
detailed in Table 1.
CTL were generated from all animals and tested against
autologous cell lines infected with five cloned sporozoite
stabilates and an MHC-mismatched infected cell line as
control. Figure 1 shows an example of the results for a CTL
assay of one of the animals. For simplicity, the cytotoxicity
for all animals at the same effector/target ratio of 10:1 was
deduced from dilution curves, as shown in Fig. 1. The re-
sults for all animals, as shown in Table 2, allows a compari-
son of the breadth of specificity to five different parasite
strains exhibited by CTL from the Muguga-immunized and
the Muguga cocktail-immunized calves. ANOVA analysis
confirmed that there were no statistically difference (P = 0.
421). Importantly, CTL from the Muguga-immunized ani-
mals killed all five targets to various degrees and no clear
strain specificity was observed. CTL from BH047 showed a
consistently lower level of killing compared to the other
CTL, despite several attempts to establish a bulk culture
showing higher cytotoxicity.
CTL from the Muguga cocktail-immunized animals
were also assessed for recognition of all three
components present in the Muguga cocktail. As seen in
Table 3, all Muguga cocktail-immunized animals showed
killing of the three components. Interestingly, the
Muguga component was killed more effectively in all
cases (P < 0.001 for each of the cattle) except BH047,
where the killing of the Serengeti component was
slightly greater (not statistically significant). As there can
be variability in CTL assays, these experiments were
done at least twice, and for some animals three times,
and the results were similar.
Cloned CTL from a haplotype-matched pair show similar
strain specificities
To examine the CTL specificity in more detail, we gen-
erated CTL clones from one haploidentical pair, namely
the A12/A14 pair of BG053 and BG051. We also suc-
cessfully generated clones from BG052 (results not
shown) but not from the rest of the animals. Each clone
Fig. 1 Example of the result from a CTL assay. Serial dilutions of CTL
from BG052 were tested for lysis of fixed numbers of the various
target cells shown in the figure. The dashed line represents the
deduced specific killing at an effector:target ratio (E:T ratio) of 10:1
for the target Muguga 3308. This method was used to compare
killing of the various target cells as listed in Table 2. Each point
represents the average of a double-determination with the
SD shown
Table 2 Cytotoxic T cell responses in immunized cattle assayed
on target cells infected with different cloned T. parva strains
Muguga Uganda
3308
Mariakani
3645
Boleni
3212
Marikebuni
3230
Control
3292
BG033 (M) 34 13 35 16 ND 0
BG042 (C) 26 18 17 9 18 0
BG053 (M) 59 40 14 20 34 0
BG051 (C) 51 25 38 22 28 3
BG052 (M) 38 33 25 23 17 4
BG056 (C) 3 22 20 11 13 3
BH055 (M) 40 30 26 13 20 0a
BH047 (C) 10 8 8 7 4 0
Cytotoxic T cell responses using autologous PBMC infected with different
cloned T. parva strains as target cells. The specific cytotoxicity at effector/
target ratios of 10:1 are shown. Each value is deduced from an effector (CTL)
titration curve as shown in Fig. 1. (M) Muguga 3308 immunized; (C) Muguga
cocktail immunized. (ND) Not determined, (a) Control was autologous PBMC.
Relative differences of the CTL specificities, between M and C, were tested
using ANOVA analysis (P = 0.421)
Table 3 Cytotoxic T cell responses in cattle immunized with the
Muguga cocktail on the three T. parva component strains as
targets
Muguga
4230
Serengeti
4229
Kiambu 5
4228
Control
BG042 26a 18 13 0
BG051 40a 28 34 0
BG056 27a 22 15 0
BH047 9 11 5 0
Cytotoxic T cell responses by vaccine immunized animals using autologous
PBMC infected with the three different T. parva component strains as targets.
Each CTL was titrated on a fixed number of target cells. The effector/target
ratio of 10:1 is shown and each value is deduced from an effector (CTL)
titration curve as shown in Fig. 1. Statistical comparison of parameters from
fitted curves were used to test differences in cytotoxicity between targets. (a)
significant higher than for both other targets for each animal (p < 0.001)
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was tested for cytotoxicity using the five different cloned
sporozoite strains as target cells. Figure 2a shows a heat
map of the clonal analysis of BG053 which was immu-
nized with Muguga 3308. It is clear from the pattern of
recognition that nine different clonotypes from BG053
were identified, with some clones recognizing only one
or two strains, and others recognizing three or four of
the five strains. The least recognized strain was
Marikebuni, and only one clone was found that recog-
nized Muguga alone. In general, the clonal analysis cor-
responded well with the bulk analysis, where strongest
killing was also observed with the Muguga and Uganda
stabilates. On the other hand, few of the clones recog-
nized Marikebuni in contrast to the results observed
with the bulk cell lines.
The clonal analysis of the Muguga cocktail-immunized
animal BG051 is shown in Fig. 2b. Eight clonotypes were
identified, with a surprisingly high number of clones
specific for Kiambu5 only. There were also clones which
recognized a broader set of targets. As observed in the
analysis of bulk CTL lines, there was no evidence from
the clonal analysis of a wider set of clonal reactivities in
the Muguga cocktail-immunized animal compared to
the Muguga only-immunized animal. Table 4 shows the
number of clones with the percentages in brackets, that
recognize indicated numbers of different cloned strains
(upper part), and the number of clones with percentage
in brackets recognizing a particular parasite strain (lower
part). It is evident that a large fraction of clones from
the Muguga cocktail-immunized animal recognized one
strain only, whereas more clones from the Muguga only-
immunized animal recognized many of the strains,
which is opposite of what was expected. All clones from
the Muguga only-immunized animal recognized Muguga
as expected, and 89% recognized Uganda, implying that
this strain is quite similar to Muguga. On the other
hand, Marikebuni was the least recognized strain, being
specifically lysed by only 17% of the clones. In the
Muguga cocktail-immunized animal, 87% of the clones
recognized Kiambu5, one of the components in the
vaccine, compared to 5% and 16% that recognized the
Muguga and Serengeti-transformed components,
a b
Fig. 2 Cytotoxicity obtained by T cell clones on a panel of target cells infected with different cloned T. parva strains. The cutoff value was 5% cytotoxicity.
Clones were categorized into clonotypes based on their pattern of reactivity. The level of cytotoxicity is visualized as a heat map – colour codes are shown.
a Calf BG053 immunized with Muguga 3308. CD8 T cell clones were generated from CD8-purified bulk cultures and tested for cytotoxicity to 5 different
strains (as shown) and a MHC-mismatched control TpM. b The haplotype-matched calf BG051 immunized with the Muguga cocktail 0801. Clones were
tested for cytotoxicity on the same target cells as BG053 and the additional components of the Muguga Cocktail
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respectively. Interestingly, there was a difference in the two
Muguga-infected targets, which may reflect qualitative dif-
ferences in presented epitopes in these two target cells.
In summary, the results of the CTL assays do not
support the hypothesis that immunization with the
Muguga cocktail induces CTL with a broader reactiv-
ity against T. parva-infected cell lines compared to
immunization with the Muguga stabilate alone, at
least with the parasite strains and MHC haplotypes of
the animals assessed here.
Similar protection to the vaccine strains in animals
vaccinated with Muguga or the Muguga cocktail
The animals were challenged with the Muguga cocktail
in order to investigate if there were any differences be-
tween the Muguga-immunized animals and the Muguga
cocktail-immunized animals in their immunity to para-
site strains present in the Muguga cocktail vaccine but
not in the Muguga stabilate. Two non-immunized con-
trol animals were used to confirm a sufficient challenge
had been delivered and the clinical outcome was
assessed with the Rowlands ECF index [30]. The experi-
ment was stopped at day 14 as there was no develop-
ment of disease in the animals except for the two
control animals. As seen in Table 5, there was no sub-
stantive difference in the protection to the Muguga
cocktail between animals immunized with Muguga only
or the Muguga cocktail. Only one animal from each im-
munized group developed pyrexia, and schizonts were
detected in three of the seven animals, two from the
Muguga-immunized group and one from the Muguga
cocktail-immunized group. This contrasts strongly with
the control animals, both of which developed pyrexia
and had detectable schizonts and piroplasms. Interest-
ingly, the animal with the highest ECF score, BH047,
was the animal with the weakest CTL response.
Discussion
It is of major importance to fully understand the mecha-
nisms underlying the protective immune response to T.
parva, both to underpin the deployment of the current
live Muguga cocktail vaccine and to guide the develop-
ment of a subunit vaccine.
The Muguga cocktail vaccine is composed of parasites
from three different isolates (Muguga, Kiambu 5 and
Serengeti-transformed), and it is known to protect
Table 4 Number and percentages of CTL clones from BH053
and BH051 recognizing multiple T. parva strains
Calf BG053 (M) BG051 (C)
Total 18 38
1 strain 1 (6) 29 (76)
2 strains 5 (28) 2 (5)
3 strains 5 (28) 2 (5)
4 strains 7 (39) 4 (11)
5 strains 0 (0) 1 (3)
Muguga (4230) ND 2 (5)
Serengeti (4229) ND 6 (16)
Kiambu-5 (4228) ND 33 (87)
Muguga (3308) 18 (100) 2 (5)
Uganda (3645) 16 (89) 7 (18)
Mariakani (3212) 9 (50) 5 (13)
Boleni (3230) 8 (44) 1 (3)
Marikebuni (3292) 3 (17) 6 (16)
Upper part of the table: The total number of clones with percentages in brackets, that
recognize multiple cloned T. parva strains, with a cutoff value of 5% cytotoxicity, for
the haplotype matched pair, BG053 (Muguga immunized) and BG051
(Muguga cocktail immunized), is shown. Each clone was analyzed for the
number of strains that it recognized. The left numbers in each column
represents the actual number of clones recognizing 1 strain, 2 strains, etc.
The numbers in brackets represents the corresponding percentages of clones
recognizing 1 strain, 2 strains etc. Percentages have been rounded. Lower part of
the table: The total number of clones and percentages in brackets from BG053
and BG051 recognizing the different T. parva strains. Percentages have been
rounded. BH051 was tested on the Muguga cocktail component reference
stabilate strains in addition to the cloned strains. (ND) Not determined
Table 5 Challenge of cattle with the Muguga cocktail 0801
Animal Immunization Days with Schizonts Days with pyrexia Days with piroplasms Day treated ECF index
BG033 Mug 3308 (M) 5 1.04
BG053 Mug 3308 (M) 2 2.21
BH055 Mug 3308 (M) 2 2.43
BG051 Vac 0801 (C) 1.04
BG042 Vac 0801 (C) 1.04
BH047 Vac 0801 (C) 6 4 2.98
BG056 Vac 0801 (C) 1.04
BG039 None 7 5 2 13 6
BH043 None 7 4 2 13 5.93
All 7 immunized cattle (BG052 succumbed for unknown reasons) and two naïve control cattle BG039, BH043 were challenged with the Muguga cocktail vaccine
stabilate 0801. Number of days with schizonts, pyrexia, piroplasms and the days until treatment are indicated. The ECF index is also indicated
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animals efficiently when deployed in the field [5], despite
the presence of antigenic variation in field populations
of the parasite [31]. The experiments reported in this
article were undertaken to demonstrate that the trivalent
Muguga cocktail vaccine provided a more complete pro-
tection against heterologous challenge than the Muguga
stabilate alone by inducing CTLs capable of recognizing
a broader range of parasite strains.
Surprisingly, there was no substantive difference in the
CTL responses to the different T. parva strains between
MHC-matched animals immunized with the Muguga
cocktail and the Muguga only. The clonal analysis of
one of the haplotype matched pairs supported these re-
sults (unfortunately we were not able to generate clones
from the other haplotype matched pairs). We were sur-
prised to see the many Kiambu 5-specific clones from
the vaccine immunized BG051 animal. This result did
not corroborate with the bulk result (Table 2), where
there were good responses to Muguga and to Serengeti.
It is possible that there is a bias in the cloning process in
some cases. Some clones could be easier to expand than
others, which would limit the interpretation of the clonal
analyses in general. Nevertheless, the bulk results also
did not favour a broader CTL specificity in the Muguga
cocktail immunized animals compared to those immu-
nized with the Muguga stabilate. An interesting observa-
tion was that certain clones recognized many different
target cells, which shows that there are indeed broadly
cross-reactive antigenic determinants which induce a
CTL response following ITM immunization, either with
Muguga alone or with the Muguga cocktail. Future work
will aim to map these epitopes, which could be useful in
a subunit vaccine.
Previous research on the strain specificity of the CTL
response in animals immune to T. parva suggests that
the response in each animal is dominated by a small
number of antigens [10, 11, 19, 20]. Clonal analysis of
the response in MHC-homozygous animals confirmed
this immunodominance by showing that over 60% of the
clones from the animals recognized single epitopes in
the two respective antigens presented by the MHC hap-
lotypes [24]. The relatively high number of clonotypes
observed in the A12/A14 animals analysed here suggests
that this is not the case in these animals, unless there is
an immunodominant antigen which displays antigenic
diversity. In other words, the differential reactivity of the
clonotypes is a consequence of the different levels of
cross-reactivity of each clone with variant forms of a
dominant epitope. The T. parva antigens recognized by
the various MHC alleles in the A12 and A14 animals have
not been fully identified so it is currently not possible to
assess the recognition of specific epitopes and the level of
diversity displayed by such epitopes. The focus of the
response in the Muguga cocktail-immunized animal on
Kiambu 5 is interesting and may reflect an immunodomi-
nant antigen found predominantly in Kiambu and not
shared with many other strains. In this respect, it would
be interesting to assess whether CTL from Muguga-only
immunized animals are cytotoxic towards the three com-
ponents in the Muguga cocktail, and to assess whether
CTL derived from animals immunized with any one of
the components comprising the Muguga cocktail
recognize the cloned strains as this may reveal if there
are immunodominant, cross-reactive epitopes in the
stabilates, and whether this outcome is dependent on
the MHC background of the animals.
In order to show if the lack of differences in the CTL
responses was reflected in vivo, all animals were chal-
lenged with a lethal dose of the Muguga cocktail. There
were no major differences in the protection observed in
the animals, which indicates that there are no important
differences in the antigenic composition of the Muguga
stabilate and the Muguga cocktail, at least in animals of
the MHC types studied here. This result is perhaps not
surprising, as the orginal studies of Radley et al., (1975a)
showed that the Muguga stabilate provided good protec-
tion against both the Kiambu 5 and Serengeti trans-
formed stabilates, and vice versa. In addition, recent
deep-sequencing results from our group have also
shown that the Muguga cocktail does not contain a great
amount of diversity in the known CTL antigens which
were examined [32]. Five of the nine antigen genes se-
quenced were present as a single version, with three
present in two forms and the final as three variants.
These results suggest that the three components are an-
tigenically very similar and they invoke the question of
why the Muguga cocktail provided better protection in
the original experiments and why the Muguga cocktail
has been so successful in protecting animals against field
challenge, where heterogeneous challenges will be far
more predominant. It may be, as argued elsewhere [33],
that antigenic diversity in the vaccine stabilate is not as
essential as originally believed. A note of caution is that
most of the antigens which have been sequenced are
those presented by predominantly European cattle, and
may not reflect important antigens recognized in breeds
where the vaccine has been deployed.
These results are somewhat contradictory to the earl-
ier study, where it was shown that a mixture of Muguga,
Kiambu5 and Serengeti transformed stabilates provided
better protection than individual stabilates [34]. It
should be noted that a different challenge strain
(Kiambu 1) was used in the earlier experiment. Thus, a
possible explanation for the difference in results is that
the CTL induced by the Muguga isolate do not cross-
react with antigens present in Kiambu 1, at least in the
animals of the MHC types used in the earlier experi-
ment. This experiment was performed before the role of
Steinaa et al. BMC Veterinary Research  (2018) 14:145 Page 7 of 9
CTL as the mediators of immunity and the influence of
the MHC were established, and the MHC types of the
animals are not available.
However, the difference in the results does indicate
that, although we have shown that Muguga-immunized
animals of the MHC types used here can generate CTL
of similar strain specificities as those immunized with
the Muguga cocktail, we cannot with certainty state that
use of the Muguga isolate alone will provide the same
broad protection in the field as the Muguga cocktail ap-
pears to provide. In this respect, it would also be inter-
esting to test if cattle immunized with either Muguga
only or the Muguga cocktail would be protected if chal-
lenged with the strains, that previously were shown to
break through single-strain immunization, such as
Marikebuni and Kiambu 1, this time with a larger num-
ber of cattle per group.
The field situation is far more complicated than the
experimental conditions employed here, due to the pres-
ence of a much more heterogenous population of para-
sites and the diversity of MHC types in outbred cattle
populations of several breeds. Both of these factors
threaten the success of vaccines composed of a limited
number of parasite strains. Particularly at risk are cattle
populations in the buffalo-cattle interface, as parasites
derived from buffalo show much greater antigenic diver-
sity than those from cattle [31]. Indeed, it has been
shown that immunization with the Muguga cocktail
does not protect cattle in areas of close interaction with
buffalo [35], although it has not been established that
this is due to antigenic diversity. Close monitoring of
break-through incidences in the field with use of the
Muguga cocktail versus single strains would show
whether or not single strains protect as well as the
Mugaga cocktail.
Conclusion
There were no indications that a broader immune response
was induced by immunization with the Muguga cocktail
compared to the Muguga strain only, in the haplotypes ex-
amined in this study. In agreement with this, previous stud-
ies on antigenic diversity in the Muguga cocktail found
limited diversity. As the original studies using single strain
and Muguga cocktail for induction of protection were per-
formed with limited number of animals and with high
doses of needle challenges, this may warrant for testing sin-
gle vaccine strains in field settings where the load of para-
sites during challenge will be much lower.
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